Building the Future: London’s Life Sciences Stories

Discover how London’s innovators are transforming the future of health.

Join us for Life Sciences: Innovation in Action, an in-person panel showcasing breakthrough technologies emerging right here in London — from AI-driven diagnostics to life-saving medical devices. Hear from the founders and scientists turning big ideas into real-world impact, and connect with the people shaping the region’s growing life sciences powerhouse.

Panelists:

Dan Sinai 
President & CEO
Episign Inc.

Dan Sinai joined Episign in August 2023 as their first CEO. Dan is an accomplished Innovation Leader with over 37 years of diverse experience across technology, research, and business development sectors. Prior to joining Episign, Dan served as a Senior Executive at IBM’s Canadian R&D Centre enhancing innovation initiatives nationally by connecting start-ups with IBM’s technological platforms and enterprise clients.

Earlier in his career, Dan was integral to the University of Western Ontario, where he facilitated strategic research plans and managed key research services. He also demonstrated his leadership at the Canadian Language and Literacy Network Inc., where he supported nationwide research and knowledge exchange programs. Dan’s extensive background in leading high-profile innovation efforts in industry, government and educational sectors showcases his capability to navigate complex challenges and lead organizations towards ground-breaking achievements.
 

EpiSign Inc. is a Canadian bioinformatics company focused on epigenetic diagnostics. Their flagship offering, EpiSign™, uses machine learning and genome-wide DNA methylation profiling (episignatures) to assist in diagnosing rare genetic and environmental exposure–related disorders that traditional genetic tests may miss.

Norm Tiffin 
President & Managing Partner 
GFR90

Norm holds a Masters’ degree in healthcare as a practicing respiratory therapist and clinical researcher he became interested in the development and marketing of medical products. He has brought to market 12 products including as an inventor, investor, researcher/author, national distributor and global VP of marketing. He, and his CEO, Don Bilyea, have been involved in the development and commercializing of GFR90’s wearable artificial kidney for over 5 years.
 

GFR90 is developing and commercializing a wearable artificial kidney. The ability for patients with kidney failure to dialyze virtually continuously addresses many of the medical, social, economic and quality of life issues that accompany intermittent in-clinic dialysis. We have successfully completed two clinical trials and have issued Canadian and pending USA patents. We are looking for further funding.

Megan Hutter
Chief Technical Officer, Co-founder 
NovaSonix Healthcare

Megan leads technological development and innovation at NovaSonix Healthcare, a start-up focused on advancing musculoskeletal health through cutting-edge 3D ultrasound solutions. Megan is a current PhD candidate in Biomedical Engineering, with experience in medical imaging and 3D ultrasound technology. Megan is committed to advancing portable imaging technology to improve access and ultimately transform patient care.

NovaSonix Healthcare is transforming musculoskeletal (MSK) imaging with MSKNovaVue™, an attachment that turns any standard ultrasound machine into a real‑time 3‑dimensional scanner. Designed to work with any commercially available ultrasound machine, MSKNovaVue™ automatically captures full 3D images in seconds, while on‑board AI algorithms quantify disease biomarkers such as cartilage thickness and joint inflammation.

Across North America, limited MRI capacity has become the bottleneck in musculoskeletal (MSK) care. In Canada, the average wait for a medically necessary MRI is roughly 90 days; and in the U.S., scans occur more than 10 days after referral, delaying care for millions. With one in two adults affected with MSK disorders, weeks-to-months of delayed diagnosis lead to chronic pain, repeat injuries, and avoidable surgeries—an economic drag exceeding US$64B in lost productivity and added medical costs. Reducing imaging backlogs is both a clinical imperative and a multi-billion-dollar opportunity.

NovaSonix Healthcare addresses this with MSKNovaVue™️, a compact attachment that converts any standard ultrasound into a real-time 3-D scanner. MSKNovaVue™️acquires true volumetric data in seconds and uses on-board AI to quantify MSK biomarkers such as cartilage thickness and joint inflammation, delivering MRI-like insight at the point of care without MRI-level cost or wait times.